



Nrf2 in Acute and Chronic Neurological Disorders

Guest Editor:

Prof. Dr. Sylvain Doré

Department of Anesthesiology,
Neurology, Psychiatry, and
Neuroscience, University of
Florida, 1275 Center Drive
Gainesville, FL 32610-0254, USA

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

There is a lack of effective neuroprotective therapies for both acute and chronic neurological disorders. Nrf2 is a transcription factor that aids in regulating cellular and organismal protection and plays a crucial role in firmly controlling redox homeostasis and inflammation in the body. Consequently, the pleiotropic nature of Nrf2 has unique therapeutic potential for the prevention and treatment of both acute and chronic diseases of the central nervous system. The advantage of targeting transcription factor Nrf2 lies in its ability to activate several downstream neuroprotective proteins and enzymes. Nrf2 has been shown to delay necrosis and cell death, reduce cell edema and inflammation, improve function and survival of all cells in the brain, and restore normal flow. It may provide brain resistance against a primary or chronic series of insults. Due to extensive evidence regarding the neuroprotection and benefits of Nrf2 in preclinical models, it is now recommended to test brain-penetrant Nrf2-activating drugs to treat these various neurological deteriorations in rigorous double-blinded clinical trials.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Alessandra Napolitano

Department of Chemical
Sciences, University of Naples
"Federico II", Via Cintia 4, I-80126
Naples, Italy

Message from the Editor-in-Chief

It has been recognized in medical sciences that in order to prevent adverse effects of "oxidative stress" a balance exists between prooxidants and antioxidants in living systems. Imbalances are found in a variety of diseases and chronic health situations. Our journal *Antioxidants* serves as an authoritative source of information on current topics of research in the area of oxidative stress and antioxidant defense systems. The future is bright for antioxidant research and since 2012, *Antioxidants* has become a key forum for researchers to bring their findings to the forefront.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, FSTA, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Chemistry, Medicinal) / CiteScore - Q1 (Food Science)

Contact Us

Antioxidants Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antioxidants
antioxidants@mdpi.com
[X@antioxidants_OA](https://twitter.com/antioxidants_OA)